[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[2] Virnig BA, Shamliyan T, Tuttle TM, et al.Diagnosis and management of ductal carcinoma in situ (DCIS)[J]. Evid Rep Technol Assess (Full Rep),2009(185):1-549.
[3] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[4] Sanders ME, Schuyler PA, Dupont WD, et al.The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up[J]. Cancer,2005,103(12):2481-2484.
[5] Collins LC, Tamimi RM, Baer HJ, et al.Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study[J]. Cancer,2005,103(9):1778-1784.
[6] Kuerer HM, Albarracin CT, Yang WT, et al.Ductal carcinoma in situ: state of the science and roadmap to advance the field[J]. J Clin Oncol,2009,27(2):279-288.
[7] Page DL, Dupont WD, Rogers LW, et al.Intraductal carcinoma of the breast: follow-up after biopsy only[J]. Cancer,1982,49(4):751-758.
[8] Dieterich M, Hartwig F, Stubert J, et al.Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival[J]. Breast,2014,23(4):346-351.
[9] Kim JY, Han W, Moon HG, et al.Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor[J]. Clin Breast Cancer,2013,13(5):385-391.
[10] Chagpar AB, McMasters KM, Sahoo S, et al. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?[J]. Surgery,2009,146(4):561-567;discussion 567-568.
[11] Wu SG, Zhang WW, Sun JY, et al.Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a surveillance, epidemiology, and end results database analysis[J]. Cancer Manag Res,2018,10:527-534.
[12] Mylonas I, Makovitzky J, Jeschke U, et al.Expression of Her2/neu, steroid receptors (er and pr), ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (dcis) versus invasive breast cancer alone[J]. Anticancer Res,2015,25(3A):1719-1723.
[13] Wilkinson NW, Shahryarinejad A, Winston JS, et al.Concordance with breast cancer pathology reporting practice guidelines[J]. J Am Coll Surg,2003,196(1):38-43.
[14] Wong H, Lau S, Yau T, et al.Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer[J]. Br J Cancer,2010,102(9):1391-1396.
[15] Bombonati A, Sgroi DC.The molecular pathology of breast cancer progression[J]. J Pathol,2011,223(2):307-317.
[16] Casasent AK, Edgerton M, Navin NE.Genome evolution in ductal carcinoma in situ: invasion of the clones[J]. J Pathol,2017,241(2):208-218.
[17] Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al.Breast cancer precursors revisited: molecular features and progression pathways[J]. Histopathology,2010,57(2):171-192.
[18] Logullo AF, Godoy AB, Mourao-Neto M, et al.Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma[J]. Braz J Med Biol Res,2002,35(8):913-919.
[19] Lopez GS, Blanch FJ, Lopez-Gordo E, et al.Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study[J]. Int J Surg,2019,63:98-106.
[20] Lampejo OT, Barnes DM, Smith P, et al.Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component[J]. Sem Diagn Pathol,1994,11(3):215-222.
[21] Park TS, Hwang ES.Current trends in the management of ductal carcinoma in situ[J]. Oncology (Williston Park),2016,30(9):823-831.
[22] Gebreamlak EP, Niu Y.Low-grade and high-grade invasive ductal carcinomas of the breast follow divergent routes of progression[J]. Clin Oncol Cancer Res,2011,8(3):123-127.
[23] Roylance R, Gorman P, Hanby A, et al.Allelic imba-lance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways[J]. J Pathol,2010,196(1):32-36.
[24] Douglas-Jones AG, Gupta SK, Attanoos RL, et al.A cri-tical appraisal of six modern classifications of ductal carcinoma in situ of the breast(DCIS): correlation with grade of associated invasive carcinoma[J]. Histopathology,1996, 29(5):397-409.
[25] Azzopardi JG, Chepick OF, Hartman WH, et al.Epithelial Tumors[M]//WHO. Histological Typing of Breast Tumors. 2th ed. Geneva: WHO publication,1981:17-22
[26] Lester SC, Bose S, Chen YY, et al.Protocol for the examination of specimens from patients with invasive carcinoma of the breast[J]. Arch Pathol Lab Med,2009,133(10):1515-1538.
[27] Krishnan L, Jewell WR, Krishnan EC, et al.Breast cancer with extensive intraductal component: treatment with immediate interstitial boost irradiation[J]. Radiology,1992, 183(1):273-276.
[28] Touboul E, Buffat L, Belkacemi Y, et al.Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer[J]. Int J Radiat Oncol Biol Phys,1999,43(1):25-38.
[29] Cedolini C, Bertozzi S, Londero AP, et al.Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer[J]. Int J Clin Exp Pathol,2015,8(10):13304-13313.
[30] Perou CM, Sorlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
[31] Sorlie T, Perou CM, Tibshirani R, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A,2001,98(19):10869-10874.
[32] Steinman S, Wang J, Bourne P, et al.Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast[J]. Ann Clin Lab Sci,2007,37(2):127-134.
[33] Lesurf R, Aure MR, Mork HH, et al.Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer[J]. Cell Rep,2016,16(4):1166-1179.
[34] Kim JY, Lee E, Park K, et al.Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes[J]. Oncotarget,2017,8(17):27997-28007.
[35] Miron A, Varadi M, Carrasco D, et al.PIK3CA mutations in in situ and invasive breast carcinomas[J]. J Cancer Res,2010,70(14):5674-5678.
[36] Tamimi RM, Baer HJ, Marotti J, et al.Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer[J]. Breast Cancer Res,2008,10(4):R67.
[37] Creighton CJ.The molecular profile of luminal B breast cancer[J]. Biologics,2012,6:289-297.
[38] Citri A, Yarden Y.EGF-ERBB signalling: towards the systems level[J]. Nat Rev Mol Cell Biol,2006,7(7):505-516.
[39] Elsarraj HS, Hong Y, Valdez KE, et al.Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion[J]. Breast Cancer Res,2015,17:128.
[40] Doebar SC, van den Broek EC, Koppert LB, et al. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study[J]. Breast Cancer Res Treat,2016,158(1):179-187.
[41] Lee JS, Oh M, Ko S, et al.IHC-breast cancer subtypes of invasive ductal carcinoma with predominant intraductal component as an insignificant prognostic factor: A register-based study from Korea[J]. Cancer Treat Commun,2016,7:52-57.
[42] Wong H, Lau S, Leung R, et al.Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer[J]. Med Oncol,2012,29(3):1536-1542.
